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Clinical PerspectiveWhat Is New?Among patients with heart failure with reduced ejection fraction, left ventricular ejection fraction improves in a third. Patients with heart failure with improved ejection fraction (HFiEF) have better prognosis than other heart failure phenotypes.Younger age, female sex, de novo onset, hypertension, atrial fibrillation, and β‐blocker prescription are positive predictors, whereas ischemic heart disease and diabetes mellitus are negative independent predictors of HFiEF.The use of β‐blockers, but not renin--angiotensin system inhibitors or mineralocorticoid receptor antagonists, is associated with reduced all‐cause mortality among patients with HFiEF.What Are the Clinical Implications?HFiEF is a distinct heart failure phenotype with better clinical outcomes than other phenotypes.β‐Blockers should be continued in HFiEF patients.

 {#jah33928-sec-0009}

Heart failure (HF) is currently classified as HF with reduced ejection fraction (HFrEF), HF with midrange ejection fraction (HFmrEF), or HF with preserved ejection fraction (HFpEF) based on left ventricular ejection fraction (LVEF).[1](#jah33928-bib-0001){ref-type="ref"} Although the prognoses for the various HF types appear to be similar, the level of neurohumoral activity and the response to medical therapy differ among HF types, suggesting differences in their underlying pathophysiology.[2](#jah33928-bib-0002){ref-type="ref"}

Among patients with HFrEF, a subgroup experience the restoration of LVEF with goal‐directed medical therapy (GDMT) and are classified as having HF with improved ejection fraction (HFiEF).[3](#jah33928-bib-0003){ref-type="ref"}, [4](#jah33928-bib-0004){ref-type="ref"}, [5](#jah33928-bib-0005){ref-type="ref"} Data on demographics, etiology, and prognosis remain scarce, especially in Asian patients with HF.

Regarding treatment strategies, drugs targeting the sympathetic nervous system and neurohumoral activation have improved survival in patients with HFrEF[6](#jah33928-bib-0006){ref-type="ref"}, [7](#jah33928-bib-0007){ref-type="ref"}, [8](#jah33928-bib-0008){ref-type="ref"}, [9](#jah33928-bib-0009){ref-type="ref"} but not in those with HFpEF.[10](#jah33928-bib-0010){ref-type="ref"}, [11](#jah33928-bib-0011){ref-type="ref"}, [12](#jah33928-bib-0012){ref-type="ref"}, [13](#jah33928-bib-0013){ref-type="ref"} It is unknown whether HFiEF would behave like HFrEF or HFpEF in terms of response to GDMT.

KorAHF (Registry \[Prospective Cohort\] for Heart Failure in Korea) is a prospective, nationwide, multicenter cohort study that consecutively enrolled patients with acute HF (AHF), and every patient was scheduled to undergo echocardiography at baseline and at 1 year after the index admission. Using this registry, we sought to comprehensively investigate the clinical characteristics, outcomes, and response to medical therapy of patients with HFiEF.

Methods {#jah33928-sec-0010}
=======

The data that support the findings of this study are available from the corresponding author on reasonable request.

Study Population and Data Collection {#jah33928-sec-0011}
------------------------------------

KorAHF was a prospective, multicenter cohort study, and the design and preliminary results have been described elsewhere (ClinicalTrial.gov identifier NCT01389843).[14](#jah33928-bib-0014){ref-type="ref"}, [15](#jah33928-bib-0015){ref-type="ref"} Briefly, 5625 consecutive patients hospitalized for AHF in 10 tertiary university hospitals in the Republic of Korea were enrolled between March 2011 and December 2014. Patients who had signs or symptoms of HF and lung congestion, objective findings of left ventricular systolic dysfunction, or structural heart disease were included in this study. There were no exclusion criteria.

Each patient was scheduled for follow‐up at least 5 years after the index hospitalization. The mortality data of patients who were lost to follow‐up were collected from National Insurance data or National Death Records.

The institutional review board or ethics committee at each participating hospital approved the study protocol and waived the need for written informed consent. This study complied with the Declaration of Helsinki principles.

Study Variables and Definitions {#jah33928-sec-0012}
-------------------------------

All echocardiographic studies were performed by cardiologists who were certified by the Korean Society of Echocardiography, using a standard ultrasound machine with a 2.5‐MHz probe. Standard techniques were adopted to obtain M‐mode, 2‐dimensional, and Doppler measurements, in accordance with the American Society of Echocardiography\'s guidelines.[16](#jah33928-bib-0016){ref-type="ref"} LVEF was measured using the Simpson biplane method, unless the Simpson method was not possible. Based on the echocardiography findings at the index AHF hospitalization, patients were classified into those with HFrEF (LVEF ≤40%), HFmrEF (LVEF between 40% and \<50%), and HFpEF (LVEF ≥50%). All patients were encouraged to undergo follow‐up echocardiography at 1 year after the index hospitalization. Among patients with HFrEF at the index hospitalization, those whose LVEF improved to \>40% were considered to have HFiEF, whereas those with LVEF ≤40% were considered to have persistent HFrEF (Figure [1](#jah33928-fig-0001){ref-type="fig"}A).

![Study population. **A**, Flowchart of the study. **B**, Patients demographics according to the flowchart. EF indicates ejection fraction; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; KorAHF, Registry (Prospective Cohort) for Heart Failure in Korea.](JAH3-8-e011077-g001){#jah33928-fig-0001}

In terms of medication, the use of β‐blockers for HF treatment was defined as a prescription for carvedilol, metoprolol, bisoprolol, or nebivolol, according to the recommendation of the current guidelines.[1](#jah33928-bib-0001){ref-type="ref"}, [4](#jah33928-bib-0004){ref-type="ref"} Use of renin--angiotensin system (RAS) inhibitors was defined as the administration of either an angiotensin‐converting enzyme inhibitor or an angiotensin II receptor blocker. The β‐blocker name and dose were evaluated in the year following diagnosis of HFiEF. Low‐ and high‐dose β‐blockers were defined as those with 1% to 49% and ≥50% of the target dose, respectively. The target dose of the β‐blockers was based on the clinical guideline.[1](#jah33928-bib-0001){ref-type="ref"}, [17](#jah33928-bib-0017){ref-type="ref"} Medication history at admission, during admission, at discharge, and during follow‐up (at 1, 3, 6, and 12 months) was recorded in the KorAHF registry.

The primary outcome was 4‐year all‐cause mortality from time of HFiEF diagnosis.

Statistical Analysis {#jah33928-sec-0013}
--------------------

The data are presented as number and frequency for categorical variables and as mean±SD for continuous variables. For comparison between groups, the χ^2^ test (or Fisher exact test when any expected cell count was \<5 for a 2×2 table) was used for categorical variables and the unpaired Student *t* test was used for continuous variables. The chronological trends of the outcomes were expressed as Kaplan--Meier estimates and compared by β‐blocker use. The log‐rank test was performed for comparison of the differences in the clinical outcomes. A multivariable Cox proportional hazards regression model was used to determine the independent predictors of all‐cause mortality. Variables associated with mortality with a *P*\<0.05 were included as confounding variables in the multivariate analysis. As a sensitivity analysis, we performed both propensity‐score--matched (PSM) and inverse‐probability treatment‐weighted (IPTW) analysis. The propensity score was calculated using multivariable logistic regression analysis, and the PSM population was created using the nearest neighbor method without replacement in a 1:1 ratio (the following variables were included for matching: age, sex, body mass index, previous history of heart failure, hypertension, diabetes mellitus, ischemic heart disease, valvular heart disease, chronic obstructive pulmonary disease, cerebrovascular disease, atrial fibrillation, malignancy, New York Heart Association functional class, and medication history of β‐blockers, renin--angiotensin system inhibitors, and mineralocorticoid receptor antagonists). Considering reduction of participants during PSM analysis, the IPTW analysis was also performed to account for confounders. Success of PSM and IPTW analyses was assessed by calculating standardized differences in the baseline characteristics (Tables [S1](#jah33928-sup-0001){ref-type="supplementary-material"} and [S2](#jah33928-sup-0001){ref-type="supplementary-material"}). We used the "MatchIt" package for R programming for PSM analysis and the "Twang" package for IPTW analysis.

A 2‐sided *P*\<0.05 was considered statistically significant. The statistical tests were performed using IBM SPSS v23 (IBM Corp) and R v3.1.0 (R Foundation for Statistical Computing).

Results {#jah33928-sec-0014}
=======

Demographic and Clinical Characteristics {#jah33928-sec-0015}
----------------------------------------

Among 5625 patients included in the KorAHF registry, 5103 patients underwent baseline echocardiographic evaluation. Based on LVEF, 3088 (61%) patients were classified as having HFrEF, 730 (14%) as having HFmrEF, and 1285 (25%) as having HFpEF. During the following year, 889 had died and 1651 were either lost to follow‐up or did not undergo 1‐year follow‐up echocardiography; therefore, the data of 2302 patients were available for this analysis. Of these patients, 789 (34%) were finally diagnosed with persistent HFrEF, 720 (31%) with HFiEF, 322 (14%) with HFmrEF, and 471 (20%) with HFpEF (Figure [1](#jah33928-fig-0001){ref-type="fig"}B).

Tables [1](#jah33928-tbl-0001){ref-type="table"} and [2](#jah33928-tbl-0002){ref-type="table"} present clinical characteristics of patients with HFrEF at the index admission and at 1 year after index admission. In brief, patients with HFiEF had more favorable baseline characteristics: they were younger, showed a preponderance of de novo HF, and had less hypertension, diabetes mellitus, ischemic heart disease, and chronic obstructive lung disease. Change of LVEF from index admission to 1‐year follow‐up was 13.7±15.1% in all, 2.7±7.6% in persistent HFrEF, and 25.7±11.6% in HFiEF. The clinical information of other HF phenotypes is presented in Table [S3](#jah33928-sup-0001){ref-type="supplementary-material"}.

###### 

Clinical Characteristics According to HF Phenotypes at the Index Admission

                            All HFrEF (n=1509)          Persistent HFrEF (n=789)    HFiEF (n=720)             *P* Value
  ------------------------- --------------------------- --------------------------- ------------------------- -----------
  Demographic data                                                                                            
  Age, y                    62.4±15.2                   65.0±14.1                   59.5±15.8                 \<0.001
  Men                       937 (62.1)                  516 (65.4)                  421 (58.5)                \<0.001
  BMI, kg/m^2^              23.7±3.8                    23.6±3.5                    23.7±4.1                  0.507
  De novo HF                833 (55.2)                  354 (44.9)                  479 (66.5)                \<0.001
  Past medical history                                                                                        
  Hypertension              757 (50.2)                  409 (51.8)                  348 (48.3)                \<0.001
  Diabetes mellitus         495 (32.8)                  319 (40.4)                  176 (24.4)                \<0.001
  Ischemic heart disease    378 (25.0)                  267 (33.9)                  111 (15.4)                \<0.001
  Valvular heart disease    131 (8.7)                   60 (7.6)                    71 (9.9)                  0.120
  COPD                      127 (8.4)                   72 (9.1)                    55 (7.6)                  0.008
  Cerebrovascular disease   167 (11.1)                  100 (12.7)                  67 (9.3)                  0.037
  Atrial fibrillation       326 (21.6)                  163 (20.7)                  163 (22.6)                \<0.001
  Malignancy                123 (8.2)                   55 (7.0)                    68 (9.4)                  0.079
  Current smoking           341 (22.6)                  176 (22.3)                  165 (22.9)                0.777
  NYHA functional class                                                                                       
  II                        240 (15.9)                  124 (15.7)                  116 (16.1)                0.532
  III                       595 (39.4)                  302 (38.3)                  293 (40.7)                
  IV                        674 (44.7)                  363 (46.0)                  311 (43.2)                
  Physical examination                                                                                        
  SBP, mm Hg                127.7±28.2                  125.4±25.7                  130.3±30.5                0.001
  DBP, mm Hg                80.1±18.8                   77.6±16.4                   82.8±20.7                 \<0.001
  HR, beats/min             94.7±24.7                   92.5±23.5                   97.1±25.7                 \<0.001
  Laboratory examination                                                                                      
  Hemoglobin, mg/dL         13.1±2.3                    13.0±2.2                    13.2±2.3                  0.032
  Sodium, mmol/L            137.9±4.5                   137.9±4.4                   137.9±4.5                 0.772
  Potassium, mmol/L         4.4±0.6                     4.4±0.6                     4.3±0.6                   0.021
  BUN, mg/dL                24.5±14.8                   25.6±15.2                   23.2±14.2                 0.002
  Creatinine, mg/dL         1.4±1.4                     1.4±1.3                     1.4±1.5                   0.692
  BNP, pg/mL                980.5 (533.3--1856.5)       927.0 (508.5--1685.0)       1063.0 (545.0--2078.0)    0.090
  NT‐proBNP, pg/mL          4688.0 (2363.5--10 491.2)   4785.0 (2419.0--11 784.0)   4453.0 (2336.0--9531.5)   0.221
  Troponin I, ng/mL         0.06 (0.04--0.20)           0.06 (0.04--0.18)           0.06 (0.03--0.24)         0.198
  Echocardiography                                                                                            
  LAD, mm                   47.7±9.0                    48.3±8.7                    47.0±9.3                  0.004
  LVEDD, mm                 62.3±9.1                    64.5±9.0                    60.0±8.7                  \<0.001
  LVESD, mm                 53.0±9.9                    55.3±9.8                    50.5±9.5                  \<0.001
  E/e′                      21.8±11.1                   22.8±11.7                   20.6±10.3                 0.001
  RVSP, mm Hg               43.4±14.3                   44.1±14.8                   42.5±13.6                 0.083
  LVEF, %                   26.2±7.4                    25.3±7.1                    27.3±7.6                  \<0.001
  Medication                                                                                                  
  Β‐Blocker                 906 (60.0)                  453 (57.4)                  453 (62.9)                0.029
  RASi                      1186 (78.6)                 622 (78.8)                  564 (78.3)                0.813
  MRA                       840 (55.7)                  472 (59.8)                  368 (51.1)                0.001

Data are shown as n (%), mean±SD, or median (interquartile range). BMI indicates body mass index; BNP, B‐type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; LAD, left atrial diameter; LVEDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end‐systolic diameter; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal proB‐type natriuretic peptide; NYHA, New York Heart Association; RASi, renin‐angiotensin system inhibitor; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure.
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###### 

Clinical Characteristics According to HF Phenotypes 1 Year After Index Admission (ie, at HFiEF diagnosis)

                                    All HFrEF    Persistent HFrEF (n=789)   HFiEF (n=720)   *P* Value
  --------------------------------- ------------ -------------------------- --------------- -----------
  Physical examination                                                                      
  SBP, mm Hg                        118.2±18.7   114.7±17.9                 121.8±18.9      \<0.001
  DBP, mm Hg                        70.6±12.7    68.4±12.0                  72.8±12.9       \<0.001
  HR, bpm                           78.2±15.6    78.4±16.1                  78.1±15.2       0.767
  Laboratory examination                                                                    
  Hemoglobin, mg/dL                 12.7±2.1     12.8±2.1                   12.7±2.0        0.371
  Sodium, mmol/L                    139.1±3.3    138.8±3.2                  139.4±3.5       0.006
  Potassium, mmol/L                 4.5±0.5      4.5±0.5                    4.5±0.5         0.072
  BUN, mg/dL                        24.5±14.5    25.9±15.2                  22.8±13.5       0.001
  Creatinine, mg/dL                 1.5±1.6      1.6±1.5                    1.5±1.6         0.423
  Echocardiography                                                                          
  LAD, mm                           44.4±8.8     46.9±8.4                   41.6±8.4        \<0.001
  LVEDD, mm                         57.7±10.0    63.6±8.8                   51.2±6.7        \<0.001
  LVESD, mm                         44.8±12.3    53.6±9.6                   35.6±7.0        \<0.001
  E/e′                              16.7±10.2    19.8±11.4                  13.5±7.5        \<0.001
  RVSP, mm Hg                       36.8±31.6    40.3±24.2                  32.3±38.6       \<0.001
  LVEF, %                           39.9±14.8    28.0±7.4                   53.0±8.4        \<0.001
  *Δ*LVEF from index admission, %   13.7±15.1    2.7±7.6                    25.7±11.6       \<0.001
  Medications                                                                               
  Β‐Blocker                         878 (63.3)   443 (60.9)                 443 (65.8)      0.058
  RASi                              981 (70.7)   535 (74.9)                 446 (66.3)      \<0.001
  MRA                               612 (44.1)   373 (52.2)                 239 (35.5)      \<0.001

Data are shown as n (%) or mean±SD. BUN indicates blood urea nitrogen; DBP, diastolic blood pressure; E/e′, the ratio between early mitral inflow velocity and mitral annular early diastolic velocity; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; LAD, left atrial diameter; LVEDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end‐systolic diameter; MRA, mineralocorticoid receptor antagonist; RAS, renin‐angiotensin system inhibitor; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure.
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Predictors of HFiEF {#jah33928-sec-0016}
-------------------

The etiology and aggravating factors for AHF by HF phenotype are presented in Figure [2](#jah33928-fig-0002){ref-type="fig"}A and [2](#jah33928-fig-0002){ref-type="fig"}C. Compared with patients with persistent HFrEF, patients with HFiEF had less ischemic but more tachycardia‐induced cardiomyopathy.

![Etiology and aggravating factors according to HF phenotypes. **A**, Proportion of HF etiology. **B**, Top 5 etiologic causes according to the HF phenotypes. **C**, Five most common aggravating factors of acute HF according to the HF phenotypes. HF indicates heart failure; HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction.](JAH3-8-e011077-g002){#jah33928-fig-0002}

We investigated independent predictors of HFiEF in patients who were initially diagnosed as having HFrEF at baseline (Table [3](#jah33928-tbl-0003){ref-type="table"}). In the multivariable analysis, younger age, female sex, de novo HF, hypertension, atrial fibrillation, and use of β‐blockers were positive independent predictors. In contrast, diabetes mellitus, ischemic heart disease, and mineralocorticoid receptor antagonist (MRA) prescription at discharge were inversely associated with an HFiEF diagnosis.

###### 

Independent Predictors of HFiEF Among Patients With HFrEF at the Index Admission

                           OR     95% CI       *P* Value
  ------------------------ ------ ------------ -----------
  Age                      0.98   0.97--0.99   \<0.001
  Male                     0.65   0.52--0.81   \<0.001
  De novo onset            2.23   1.77--2.80   \<0.001
  Hypertension             1.31   1.05--1.65   0.020
  Diabetes mellitus        0.55   0.43--0.70   \<0.001
  Ischemic heart disease   0.58   0.45--0.76   \<0.001
  Atrial fibrillation      1.77   1.36--2.32   \<0.001
  Β‐Blocker at discharge   1.28   1.03--1.59   0.024
  MRA at discharge         0.59   0.47--0.73   \<0.001

ORs have been adjusted for age, sex, de novo heart failure, previous history of hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, cerebrovascular accident, atrial fibrillation and malignancy, New York Heart Association functional class, β‐blocker at discharge, renin--angiotensin system inhibitor at discharge, and MRA at discharge. HFiEF indicates heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; OR, odds ratio.
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Clinical Outcomes {#jah33928-sec-0017}
-----------------

The treatment and outcomes during the index hospitalization are displayed in Table [S4](#jah33928-sup-0001){ref-type="supplementary-material"}.

During 4‐year follow‐up, 116 (16%) patients with HFiEF died, all of whom had more unfavorable characteristics, as expected (Table [S5](#jah33928-sup-0001){ref-type="supplementary-material"}). Patients with HFiEF showed better prognosis (log‐rank, *P*\<0.001) than those with persistent HFrEF in crude, PSM, and IPTW cohorts (Figure [3](#jah33928-fig-0003){ref-type="fig"}, Tables [S1](#jah33928-sup-0001){ref-type="supplementary-material"} and [S2](#jah33928-sup-0001){ref-type="supplementary-material"}). Clinical outcomes of other HF phenotypes are presented in Figure [S1](#jah33928-sup-0001){ref-type="supplementary-material"}. Briefly, those with HFiEF had the lowest mortality (116 deaths, 16.1%) compared with those with persistent HFrEF (270 deaths, 34.2%), HFmrEF (214 deaths, 33.5%), and HFpEF (149 deaths, 31.6%).

![Clinical outcomes according to HFiEF and persistent HFrEF. **A**, Kaplan--Meier survival curves for 4‐year mortality according to HF phenotypes. As sensitivity analyses, the PSM cohort (**B**) and the IPTW cohort (**C**) were also analyzed. The curves are left‐truncated at 4 years after index admission. HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IPTW, inverse‐probability treatment weighted; PSM, propensity score matching.](JAH3-8-e011077-g003){#jah33928-fig-0003}

GDMT in HFiEF {#jah33928-sec-0018}
-------------

Regarding the effect of GDMT in HFiEF, patients with β‐blockers had lower 4‐year all‐cause mortality in crude, PSM and IPTW populations (Figure [4](#jah33928-fig-0004){ref-type="fig"}, Table [S6](#jah33928-sup-0001){ref-type="supplementary-material"}, Figure [S2](#jah33928-sup-0001){ref-type="supplementary-material"}).

![Impact of GDMT on 4‐year mortality in HFiEF patients (**A**) and persistent HFpEF patients (**B**). GDMT indicates goal‐directed medical therapy; HFrEF, heart failure with reduced ejection fraction; HFiEF, heart failure with improved ejection fraction; MRA, mineralocorticoid receptor antagonists; RASi, renin--angiotensin system inhibitor.](JAH3-8-e011077-g004){#jah33928-fig-0004}

In multivariate analysis, only the use of β‐blockers was associated with a 41% reduced risk of mortality (hazard ratio: 0.59; 95% CI, 0.40--0.87; *P*=0.007), whereas the effect of RAS inhibitor and MRA use on mortality appeared to be neutral (Table [4](#jah33928-tbl-0004){ref-type="table"}).

###### 

Cox Regression Analysis for 4‐Year Mortality From HFiEF Diagnosis

                                 Unadjusted   Adjusted                                   
  ------------------------------ ------------ ------------ --------- ------ ------------ ---------
  Age                            1.06         1.04--1.07   \<0.001   1.05   1.03--1.06   \<0.001
  Male                           1.28         0.88--1.87   0.198                         
  De novo onset                  0.41         0.28--0.59   \<0.001   0.53   0.35--0.79   0.002
  Hypertension                   1.99         1.36--2.90   \<0.001   0.96   0.60--1.52   0.852
  Diabetes mellitus              2.41         1.67--3.48   \<0.001   1.39   0.90--2.16   0.140
  Ischemic heart disease         2.93         1.98--4.33   \<0.001   1.56   0.99--2.46   0.055
  COPD                           1.01         0.51--2.00   0.971                         
  Cerebrovascular disease        3.21         2.07--4.96   \<0.001   2.09   1.29--3.38   0.003
  Atrial fibrillation            0.78         0.52--1.18   0.234                         
  Malignancy                     1.52         0.88--2.62   0.130                         
  NYHA functional class                                                                  
  II                             1            Reference    0.079                         
  III                            1.22         0.67--2.24                                 
  IV                             1.74         0.97--3.10                                 
  Β‐Blocker at HFiEF diagnosis   0.54         0.37--0.80   0.002     0.59   0.40--0.87   0.007
  RASi at HFiEF diagnosis        0.69         0.46--1.02   0.063                         
  MRA at HFiEF diagnosis         1.12         0.75--1.67   0.570                         

Adjusted hazard ratios were adjusted for variables that showed *P*\<0.05 in univariate analysis. COPD indicates chronic obstructive pulmonary disease; HFiEF, heart failure with improved ejection fraction; MRA, mineralocorticoid antagonist; NYHA, New York Heart Association; RASi, renin--angiotensin system inhibitor.
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Effect of the Dose and Timing of Initiation of β‐Blockers {#jah33928-sec-0019}
---------------------------------------------------------

Among patients with HFiEF who took β‐blockers, most received carvedilol (216 patients, 48.8%) or bisoprolol (201 patients, 45.4%) whereas nebivolol (24 patients, 5.4%) and metoprolol (2 patients, 0.5%) were rarely used. There was no difference between carvedilol and bisoprolol; however, because of the small number of patients taking metoprolol and nebivolol, a definite conclusion could not be drawn. Stratified by β‐blocker dose, patients who received either high‐ or low‐dose β‐blockers at the time of diagnosis of HFiEF showed better 4‐year mortality than those who did not; however, there was no difference between the patients who received low‐ and high‐dose β‐blockers (log‐rank, *P*=0.304; Figure [S3](#jah33928-sup-0001){ref-type="supplementary-material"}).

Because the status of β‐blocker prescription changed between discharge from the index hospitalization and the time of HFiEF diagnosis, we further categorized the patients into 4 groups according to β‐blocker use at discharge and at HFiEF diagnosis. In the Kaplan--Meier analysis, patients who were on β‐blockers at the time of HFiEF diagnosis had similar prognoses, regardless of β‐blocker use at discharge from the index hospitalization (log‐rank, *P*=0.497; Figure [S3](#jah33928-sup-0001){ref-type="supplementary-material"}).

Subgroup Analysis {#jah33928-sec-0020}
-----------------

We performed exploratory subgroup analyses that included age, sex, ischemic versus nonischemic etiology, HF onset (de novo versus acute decompensated HF \[ADHF\]), chronic kidney disease, diabetes mellitus, RAS inhibitor use, MRA use, and changes in LVEF. There was no significant interaction between the β‐blocker effect and subgroups, and β‐blocker use was consistently associated with reduced risk for 4‐year all‐cause mortality across all subgroups (Figure [S4](#jah33928-sup-0001){ref-type="supplementary-material"}).

Next, we stratified the patients by rhythm. Patients with a β‐blocker had better survival than patients without among those with sinus rhythm but not among those with atrial fibrillation (Figure [S5](#jah33928-sup-0001){ref-type="supplementary-material"}).

Regarding the onset of HF, 55% of the patients had de novo HF and 45% had ADHF. Patients with HFiEF had better survival than those with persistent HFrEF among both de novo HF and ADHF patients (Figure [S6](#jah33928-sup-0001){ref-type="supplementary-material"}). Regarding GDMT, β‐blocker use was associated with improved survival of both de novo HF and ADHF patients. In Kaplan--Meier analysis, β‐blockers showed a therapeutic implication for de novo HF (log‐rank, *P*=0.016) but attenuated improvement in ADHF (log‐rank, *P*=0.089). After adjusting for covariates, both de novo HFiEF (hazard ratio: 0.73; 95% CI, 0.54--1.00; *P*=0.049) and acute decompensated HFiEF (hazard ratio: 0.57; 95% CI, 0.33--0.98, *P*=0.041) showed a benefit of β‐blockers. In contrast, the effect of RAS inhibitors and MRAs appeared to be neutral in both de novo HF and ADHF patients (Figures [S7](#jah33928-sup-0001){ref-type="supplementary-material"} and [S8](#jah33928-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah33928-sec-0021}
==========

In this comprehensive analysis of HFiEF, we investigated the clinical characteristics, predictors, and prognostic outcomes of patients with HFiEF in comparison with persistent HFrEF. Younger age, de novo onset, and β‐blocker prescription were positive predictors; in contrast, ischemic heart disease and diabetes mellitus were negative independent predictors of HFiEF among patients with HFrEF at index admission. Compared with persistent HFrEF, patients with HFiEF had better prognosis, and the use of β‐blockers was associated with improved survival in these patients.

Clinical Characteristics and Predictors of HFiEF {#jah33928-sec-0022}
------------------------------------------------

Understanding the clinical characteristics and predictors of HFiEF provides important information and can be used for risk stratification and guidance of therapy in patients with HF. In this study, we showed that younger age and de novo HF were independent predictors of HFiEF. Previous studies also found patients with LVEF improvement to be younger.[18](#jah33928-bib-0018){ref-type="ref"} Conversely, ischemic heart disease was a strong negative predictor, in accordance with a report indicating that patients with HFiEF had less coronary artery disease.[6](#jah33928-bib-0006){ref-type="ref"} Patients with ischemic cardiomyopathy have been found to have less viable myocardium and more scarring; in addition, owing to its irreversible nature, the extent of the myocardial scar was found to correlate inversely with LVEF improvement.[19](#jah33928-bib-0019){ref-type="ref"}, [20](#jah33928-bib-0020){ref-type="ref"}

Prognosis of Patients With HFiEF {#jah33928-sec-0023}
--------------------------------

The principal finding of this study pertains to mortality, and patients with HFiEF had better prognosis compared not only with HFpEF but also with other HF phenotypes (Figure [3](#jah33928-fig-0003){ref-type="fig"}, Figure [S1](#jah33928-sup-0001){ref-type="supplementary-material"}), with a remarkably reduced risk of 4‐year all‐cause mortality. Our findings are consistent with previous studies reporting the superior long‐term clinical prognosis of patients with HFiEF compared with the other HF phenotypes.[3](#jah33928-bib-0003){ref-type="ref"}, [5](#jah33928-bib-0005){ref-type="ref"}

Notably, patients with HFiEF required more catecholamines and mechanical circulatory support device assistance during the index admission, indicating a more serious in‐hospital course in contrast to the ultimately favorable long‐term outcomes. This implies that in patients with HFrEF who survive the first year, the more serious in‐hospital course does not necessarily equate to grave long‐term postdischarge outcomes.

GDMT in HFiEF {#jah33928-sec-0024}
-------------

Another principal finding was related to the effect of GDMT in patients with HFiEF. We found that the use of β‐blockers, but not the use of RAS inhibitors or MRAs, was associated with improved survival. This finding is crucial and has important clinical implications: In patients with HFrEF, β‐blockers should be continued even after the restoration of LVEF. Interestingly, there was no difference in mortality between the patients with high‐ and low‐dose β‐blockers in our study. Considering the similar prognoses for those taking low‐ or high‐dose β‐blockers, careful dose reduction of β‐blockers may be possible for patients with HFiEF who do not tolerate β‐blockers well. Furthermore, we showed that β‐blocker use at HFiEF diagnosis was associated with improved survival regardless of the prescription of β‐blockers at hospital discharge. This finding suggests that all patients with HFiEF could benefit from β‐blocker use. The reasons for the lack of effect of RAS inhibitors and MRAs are not clear.

Strengths and Limitations {#jah33928-sec-0025}
-------------------------

This study has several limitations. First, because this study is a post hoc analysis of a prospective cohort study, albeit a large one, as opposed to a randomized controlled trial, there could be unmeasured confounding factors. Second, we enrolled only patients who underwent echocardiographic assessment at 1 year after index admission, and this approach may have led to selection and lead‐time biases, possibly favoring less ill patients or those with better compliance, in this substudy (Table [S7](#jah33928-sup-0001){ref-type="supplementary-material"}). Third, because the participants comprise only East Asian patients, it is unknown whether the results can be extrapolated to other ethnicities and countries. In addition, we assessed left ventricular systolic function by LVEF, but even patients with "normal" LVEF might have impaired left ventricular systolic function.[21](#jah33928-bib-0021){ref-type="ref"} In addition, β‐blocker, RAS inhibitor, and MRA administration may have been altered, and other factors could be related to medication during the follow‐up period. Although we evaluated the therapeutic implications of GDMT including β‐blockers, RAS inhibitors, and MRAs, further studies are necessary to validate the prognostic value of sacubitril or valsartan in patients with HFiEF. Digoxin and loop diuretics have been prevalently prescribed to manage patients with AHF, but these patients did not show significant prognostic improvement (Figure [S9](#jah33928-sup-0001){ref-type="supplementary-material"}). In addition, we defined de novo HF based on medical history of HF.[22](#jah33928-bib-0022){ref-type="ref"}, [23](#jah33928-bib-0023){ref-type="ref"}, [24](#jah33928-bib-0024){ref-type="ref"} Last, we did not perform core laboratory analysis of the echocardiographic measurement of LVEF.

This study also has specific strengths. The KorAHF registry is a well‐designed, nationwide, prospective cohort study in which every patient was scheduled to undergo echocardiography at baseline and 1 year after index admission and to be followed up for at least 5 years after index hospitalization. This design facilitates a definitive diagnosis of HFiEF, the identification of predictors, and the demonstration of its natural history; thanks to the prospective design and follow‐up schedule, the KorAHF registry could identify more patients with HFiEF than previously reported.[3](#jah33928-bib-0003){ref-type="ref"}, [5](#jah33928-bib-0005){ref-type="ref"}, [25](#jah33928-bib-0025){ref-type="ref"} Furthermore, we were also able to investigate the effect of GDMT in patients with HFiEF for the first time. Considering that LVEF improvement by GDMT was often observed between 6 and 12 months after the initiation of therapy,[26](#jah33928-bib-0026){ref-type="ref"}, [27](#jah33928-bib-0027){ref-type="ref"} echocardiographic assessment of LVEF at 1 year may be the appropriate timing for the detection of HFiEF. To minimize bias by indication, we performed several sensitivity analyses, and the protective relationship between β‐blocker use and clinical outcomes was consistent in the univariate, multivariate, PSM and IPTW analyses. Despite the strengths of this study, a randomized clinical trial is necessary to rigorously evaluate the effect of GDMT in patients with HFiEF.

Conclusions {#jah33928-sec-0026}
===========

HFiEF is a unique disease entity that has superior clinical outcomes. Younger age, de novo HF, nonischemic heart disease, and a β‐blocker prescription are independent predictors of HFiEF.
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